bioage ipo news - Search News

obesity, BioAge Labs and IPO

Fast Company · 1d

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.

Reuters on MSN · 2d

Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.

pharmaphorum · 2d

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

IPO, MNTN and Ryan Reynolds

Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing

After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.

Fast Company · 7h

Ryan Reynolds’s ad tech firm MNTN looks to Morgan Stanley for 2025 IPO

MNTN, a company that sells targeted TV advertising technology, may be working with Morgan Stanley on an initial public offering (IPO) as the firm considers its future. MNTN has already expanded significantly in recent years acquiring Hollywood star Ryan Reynolds’s agency,

Bloomberg on MSN · 16h

Ryan Reynolds’ MNTN Is Said to Tap Morgan Stanley for 2025 IPO

MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.

1don MSN

BioAge, BKV shares end their first trading day flat after earlier gains

Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.

FierceBiotech2d

BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

4h

U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.

2d

BioAge seeks nearly $200 million in initial public offering

BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results